skip to main content

S. 1048 (115th): Enhanced Clinical Trial Design Act of 2017

A bill to expand patient access to experimental treatments in clinical trials, and for other purposes.

The bill’s titles are written by its sponsor.

Sponsor and status

Orrin Hatch

Sponsor. Senator for Utah. Republican.

Read Text »
Last Updated: May 4, 2017
Length: 8 pages
Introduced:

May 4, 2017
115th Congress, 2017–2019

Status:
Introduced

Provisions of this bill were incorporated into other bills which were enacted.

This bill was incorporated into:

H.R. 2430: FDA Reauthorization Act of 2017
Enacted — Signed by the President on Aug 18, 2017. (compare text)

History

May 4, 2017
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

S. 1048 (115th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

This bill was introduced in the 115th Congress, which met from Jan 3, 2017 to Jan 3, 2019. Legislation not enacted by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 1048 — 115th Congress: Enhanced Clinical Trial Design Act of 2017.” www.GovTrack.us. 2017. February 19, 2019 <https://www.govtrack.us/congress/bills/115/s1048>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.